|
Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; EcoR1 Capital; Exelixis; Janssen; Jubilant Pharmaceuticals; Merck; Novartis; OncLive.; PCCTC; Pfizer; Tersera |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst) |
Expert Testimony - University of Utah Health |
Travel, Accommodations, Expenses - DAVA Oncology |
| |
|
Employment - Horizon Therapeutics (I) |
Stock and Other Ownership Interests - Horizon Therapeutics (I) |
| |
|
Stock and Other Ownership Interests - JJ Innovative Medicine |
| |
|
Employment - JJ Innovative Medicine |
Stock and Other Ownership Interests - JJ Innovative Medicine |
Research Funding - JJ Innovative Medicine |
| |
|
No Relationships to Disclose |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
Employment - Johnson & Johnson/Janssen |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
Patents, Royalties, Other Intellectual Property - Invention patent for invention of apalutamide for the treatment of patients with non-metastatic castration resistant prostate cancer |
Travel, Accommodations, Expenses - J&J IM |
| |
|
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics |
|
Consulting or Advisory Role - Fortis; Janssen Oncology; Teon Therapeutics |
| |
|
Research Funding - Roche (Inst) |